Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31253493 | 0.85 | SOS1 (0.53) | SOS1 | |
| SCHEMBL31253491 | 0.85 | SOS1 (0.53) | SOS1 | |
| SCHEMBL25330008 | 0.84 | SOS1 (0.55) | SOS1 | |
| SCHEMBL31253483 | 0.84 | SOS1 (0.51) | SOS1 | |
| SCHEMBL31253434 | 0.84 | SOS1 (0.55) | SOS1 | |
| SCHEMBL25330697 | 0.83 | SOS1 (0.53) | SOS1 | |
| SCHEMBL31253452 | 0.83 | SOS1 (0.53) | SOS1 | |
| SCHEMBL23326488 | 0.79 | SOS1 (0.73) | SOS1 | |
| SCHEMBL23326489 | 0.79 | SOS1 (0.73) | SOS1 | |
| SCHEMBL29849168 | 0.79 | SOS1 (0.73) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| EP-4466270-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | Shenzhen Ionova Life Science Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | KRAS, HRAS, NRAS | SOS1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.